A study to evaluate combination therapy of memantine hydrochloride with donepezil hydrochloride compared with dose escalation of donepezil hydrochloride in the patient with Alzheimer's disease who have treated with donepezil hydrochloride

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Donepezil (Primary) ; Memantine (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Therapeutic Use
Sponsors Daiichi Sankyo Company

Most Recent Events

26 Apr 2017 Status changed from active, no longer recruiting to discontinued.
22 Mar 2017 Status changed from recruiting to active, no longer recruiting.
08 Nov 2016 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight